Tag:
Trastuzumab-DM1
Latest Headlines
Latest Headlines
Roche, Genentech hit with refuse-to-file letter
The FDA has handed Roche and Genentech a refuse-to-file letter for the developers' BLA for trastuzumab-DM1. The drug attaches ImmunoGen DM1 cancer-cell killing agent to Genentech's HER2-targeting
